The Children's Hospital of Philadelphia

Sophrosyne Pharmaceuticals Limited

Tom Leyssens

Bram Harmsen

Thomas R Bailey

Richard Alan Couch

Akram Sabouni

Lewis Feldberg

Vincent Wing-Fai Tai

Michael Paul Rene Guillot

Martin Appelmans

Provided herein are novel crystalline forms of a compound that acts as an ALDH2 effector, processes for preparing the crystalline forms of the compound with or without coformer, and uses thereof.

Crystalline forms of ALDH2 modulators

The disclosure is directed to crystalline forms and mixtures thereof of R-fasoracetam. Such crystalline forms include Form II monohydrate R-fasoracetam and the anhydrate form of R-fasoracetam. The disclosure further includes mixtures of the anhydrate form of R-fasoracetam together with one or more of Form I monohydrate R-fasoracetam and Form II monohydrate R-fasoracetam.

Fasoracetam crystalline forms

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

Solid forms of fasoracetam

Growing community of inventors

Jette, Belgium

Tom Leyssens